UBS Group’s VanEck Biotech ETF BBH Stock Holding History

UBS Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,300	Closed	-$381K	–	8808
2014 Q4	$381K	Buy	+3,300	New	+$372K	﹤0.01%	4433

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

PPWM

Paragon Private Wealth Management Lexington, Kentucky $383M AUM 36.18% 1-Year Est. Return

UBS Group's BBH Position: Q2 2026 in Review

UBS Group reduced its VanEck Biotech ETF (BBH) stake by 4.7% in Q2 2026, selling an estimated $147K and leaving 15,809 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #4625.

UBS Group first reported a position in BBH in Q4 2014 and has held it in 47 quarters since. The position peaked at $24.4M in Q3 2017. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

UBS Group held 15,809 shares of VanEck Biotech ETF worth $3.21M as of Q2 2026.
UBS Group sold 784 VanEck Biotech ETF shares in Q2 2026, an estimated $147K.
VanEck Biotech ETF made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4625 holding.
UBS Group first reported a position in VanEck Biotech ETF in Q4 2014 and has held it in 47 quarters since.
UBS Group's VanEck Biotech ETF position peaked at $24.4M in Q3 2017.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.